AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study - AbbVie (NYSE:ABBV), Regeneron Pharmaceuticals (NASDAQ:REGN)

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.

Related Keywords

,Abbvie Inc ,Regeneronpharmaceutical Inc ,Eczema Area ,Severity Index ,Worst Pruritus Numerical Rating Scale ,Swipe Out ,Weak Guidance ,